Realm Therapeutics - Realm Therapeutics to Present at BIO-Europe® 2017

November 2, 2017
RNS Number : 2948V
Realm Therapeutics PLC
02 November 2017
 

 

Realm Therapeutics to Present at BIO-Europe® 2017

 

MALVERN, PA, November [2] 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the 23rd annual BIO-Europe®, a global life sciences partnering event, on Wednesday, November 8, 2017 at 12:15 p.m. CET at the CityCube Berlin in Berlin, Germany.

 

Mr. Martin will review the Company's two lead drug development programs: PR022 for Atopic Dermatitis and PR013 for Allergic Conjunctivitis. The Company remains on track to initiate Phase 2 clinical studies for both PR022 and PR013 by the end of 2017. An updated copy of Realm's corporate presentation is available on the Company's website at www.realmtx.com.

 

About Realm Therapeutics

 

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.  

 

 

Forward Looking Statements

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

 

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

+44 (0) 20 3727 1000

 

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

 

Argot Partners

Stephanie Marks

+1 212 600 1902

 

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Lauren Kettle

+44 (0) 20 7496 3000


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMMGMDMKGNZM

Search Investor Relations